Related Experiment Video
Updated: Nov 28, 2025

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
Pharmacogenetics at Scale: An Analysis of the UK Biobank
Gregory McInnes1, Adam Lavertu1, Katrin Sangkuhl2
1Biomedical Informfatics Training Program, Stanford University, Stanford, California, USA.
Abstract:
Pharmacogenetics (PGx) studies the influence of genetic variation on drug response. Clinically actionable associations inform guidelines created by the Clinical Pharmacogenetics Implementation Consortium (CPIC), but the broad impact of genetic variation on entire populations is not well understood. We analyzed PGx allele and phenotype frequencies for 487,409 participants in the UK Biobank, the largest PGx study to date. For 14 CPIC pharmacogenes known to influence human drug response, we find that 99.5% of individuals may have an atypical response to at least 1 drug; on average they may have an atypical response to 10.3 drugs. Nearly 24% of participants have been prescribed a drug for which they are predicted to have an atypical response. Non-European populations carry a greater frequency of variants that are predicted to be functionally deleterious; many of these are not captured by current PGx allele definitions. Strategies for detecting and interpreting rare variation will be critical for enabling broad application of pharmacogenetics.
Related Concept Videos
Analysis of Population Pharmacokinetic Data
Measurement of Bioavailability: Pharmacodynamic Methods
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Dosage Regimens: Partial Pharmacokinetic Parameters
Factors Affecting Drug Biotransformation: Biological
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Bioavailability Study Design: Healthy Subjects Versus Patients

